Medpace Holdings, Inc. (MEDP) Stock Analysis
Recovery setup · Temp Headwind edge
Healthcare · Diagnostics & Research
Wait for pullback to $392.72. Weak momentum — blocks BUY_NOW at $405.12. Engine's entry $392.72 (5% below current) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining.
Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical, and medical device companies, with approximately 6,200 employees across 46 countries. Revenue comes from fixed-fee and variable clinical service contracts; 82%... Read more
Wait for pullback to $392.72. Weak momentum — blocks BUY_NOW at $405.12. Engine's entry $392.72 (5% below current) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 46. Wide-moat business. Accumulate on weakness. Score 5.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 61d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Medpace Holdings, Inc.
Material events (past 30 days)
- Apr 22, 2026 MEDIUM Item 5.02: Jesse Geiger, President, notified company of intent to resign effective May 31, 2026. No successor named.
Latest news
- MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class A — PR Newswire negative
- Medpace Holdings (MEDP) Reports Strong Q1 Earnings Amid Leadersh - GuruFocus — GuruFocus positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - StockStory — StockStory positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo! Finance Canada — Yahoo! Finance Canada positive
- Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8% - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomersmall biopharmaceutical companies82%10-K Item 1A: '82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively'
- MEDIUMCustomertop-10 customers35%10-K Item 1A: 'we derive approximately 35.1% of our net revenue from our top ten customers'
Material Events(8-K, last 90d)
- 2026-04-22Item 5.02MEDIUMJesse Geiger, President, notified company of intent to resign effective May 31, 2026. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $392.72. Weak momentum — blocks BUY_NOW at $405.12. Engine's entry $392.72 (5% below current) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 46. Wide-moat business. Accumulate on weakness. Target $426.45 (+5.3%), stop $370.82 (−9.2%), Setup A.R:R 1.5:1. Score 5.7/10, moderate confidence.
Take-profit target: $426.45 (+8.6% upside). Target $426.45 (+5.3%), stop $370.82 (−9.2%), Setup A.R:R 1.5:1. Stop-loss: $370.82.
Concentration risk — Customer: small biopharmaceutical companies (82.0%); Analyst target reached - limited upside remaining; Negative momentum.
Medpace Holdings, Inc. trades at a P/E of 26.5 (forward 22.6). TrendMatrix value score: 4.4/10. Verdict: Buy (Wait for Entry).
20 analysts cover MEDP with a consensus score of 3.6/5. Average price target: $443.
What does Medpace Holdings, Inc. do?Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical,...
Medpace is a full-service clinical CRO providing Phase I–IV drug development services to biotechnology, pharmaceutical, and medical device companies, with approximately 6,200 employees across 46 countries. Revenue comes from fixed-fee and variable clinical service contracts; 82% of net revenue derives from small biopharmaceutical companies and 13% from mid-sized biopharmaceutical companies.